Mycobacterium abscessus Complex Infections in Humans

Emerg Infect Dis. 2015 Sep;21(9):1638-46. doi: 10.3201/2109.141634.

Abstract

Mycobacterium abscessus complex comprises a group of rapidly growing, multidrug-resistant, nontuberculous mycobacteria that are responsible for a wide spectrum of skin and soft tissue diseases, central nervous system infections, bacteremia, and ocular and other infections. M. abscessus complex is differentiated into 3 subspecies: M. abscessus subsp. abscessus, M. abscessus subsp. massiliense, and M. abscessus subsp. bolletii. The 2 major subspecies, M. abscessus subsp. abscessus and M. abscessus subsp. massiliense, have different erm(41) gene patterns. This gene provides intrinsic resistance to macrolides, so the different patterns lead to different treatment outcomes. M. abscessus complex outbreaks associated with cosmetic procedures and nosocomial transmissions are not uncommon. Clarithromycin, amikacin, and cefoxitin are the current antimicrobial drugs of choice for treatment. However, new treatment regimens are urgently needed, as are rapid and inexpensive identification methods and measures to contain nosocomial transmission and outbreaks.

Keywords: Mycobacterium abscessus; Mycobacterium abscessus complex; Mycobacterium bolletii; Mycobacterium massiliense; bacteria; clinical disease; cosmetic procedures; identification methods; multidrug resistant; mycobacteria; nomenclature; nontuberculous; nosocomial; outbreaks; taxonomy; transmission.

MeSH terms

  • Anti-Bacterial Agents / therapeutic use
  • Communicable Diseases, Emerging / drug therapy
  • Communicable Diseases, Emerging / epidemiology*
  • Communicable Diseases, Emerging / microbiology
  • Drug Resistance, Bacterial
  • Global Health
  • Humans
  • Mycobacterium / isolation & purification*
  • Mycobacterium Infections / drug therapy
  • Mycobacterium Infections / epidemiology*
  • Mycobacterium Infections / microbiology

Substances

  • Anti-Bacterial Agents